UCB Developed Brands
De berekende faillissementskans van UCB Developed Brands over 12 maanden bedraagt 0,8% (laag). De jaarrekening over 2025 toont een eigen vermogen van €867,82M en een nettoresultaat van €827,12M. Het bedrijf is actief sinds 2024 en het Belgisch Staatsblad bevat geen insolventie- of waarschuwingssignalen.
| Eigen vermogen | €867,82M |
| Netto resultaat | €827,12M |
| Werknemers (VTE) | 20,7 |
| Actief | 1 jaar |
Uitzonderlijk profiel, sterk op vrijwel elke as.
Statistische inschatting op basis van openbare bronnen, geen kredietadvies of vaststelling. Hoe berekenen we dit?
De volledige opbouw van de score, de scoregeschiedenis per boekjaar en de indicatieve kredietlimiet ontgrendel je met Plus.
Bekijk plannen →| Boekjaar | 2025 |
|---|---|
| Omzet | €1,25B |
| EBITDA | €1,04B |
| Nettoresultaat | €827,12M |
| Cashflow | €878,11M |
| Personeelskosten | €4,04M |
| Belastingen op het resultaat | €162,04M |
| Dividenden | - |
| Totaal activa | €1,07B |
| Eigen vermogen | €867,82M |
| Schulden | €198,40M |
| waarvan ≤ 1 jaar | €198,16M |
| waarvan > 1 jaar | - |
| Werkkapitaal | €868,74M |
| Werknemers (VTE) | 20,7 |
| 2025 | |
|---|---|
| Current ratio | 5,38 |
| Quick ratio | 5,38 |
| Werkkapitaalratio | 81,1% |
| Solvabiliteit | 81,0% |
| Debt / equity | 0,23 |
| Langetermijnschuldgraad | - |
| Interest coverage | 3893,88 |
| Bruto rentabiliteit | - |
| Netto rentabiliteit | 66,1% |
| ROA | 77,2% |
| ROE | 95,3% |
| EBITDA-marge | 83,1% |
| Klantenkrediet (DSO) | 171d |
| Leverancierskrediet (DPO) | - |
| Voorraadrotatie | - |
| Voorraaddagen (DSI) | - |
| Post | Code | 2025 |
|---|---|---|
| Balans, Activa | ||
| TOTAAL ACTIVA | 20/58 | €1,07B |
| Vaste activa | 21/28 | €4,17M |
| Immateriële vaste activa | 21 | €4,17M |
| Vlottende activa | 29/58 | €1,07B |
| Vorderingen op ten hoogste één jaar | 40/41 | €1,02B |
| Liquide middelen | 54/58 | €133 |
| Balans, Passiva | ||
| TOTAAL PASSIVA | 10/49 | €1,07B |
| Eigen vermogen | 10/15 | €867,82M |
| Inbreng / kapitaal | 10/11 | €75,73M |
| Overgedragen winst (verlies) | 14 | €792,09M |
| Voorzieningen en uitgestelde belastingen | 16 | €4,85M |
| Schulden | 17/49 | €198,40M |
| Schulden op ten hoogste één jaar | 42/48 | €198,16M |
| Handelsschulden op ten hoogste één jaar | 44 | €115,21M |
| Resultatenrekening | ||
| Omzet | 70 | €1,25B |
| Bedrijfsresultaat | 9901 | €988,80M |
| Financiële opbrengsten | 75 | €853k |
| Financiële kosten | 65 | €489k |
| Resultaat vóór belasting | 9903 | €989,16M |
| Belastingen op het resultaat | 67/77 | €162,04M |
| Resultaat van het boekjaar | 9904 | €827,12M |
| Te bestemmen resultaat | 9905 | €827,12M |
| NACE primair | 72101 |
| Rechtsvorm | BV(610) |
| Oprichtingsdatum | 17-12-2024 |
| Status | Actief |
| Postcode | 1070 |
Percelen gekoppeld aan dit bedrijf via zijn adressen in de KBO (zetel, vestigingen, bijkantoren), gekruist met het kadastraal percelenplan. Dit toont waar het bedrijf actief is, geen eigendomsregister.
| Perceel (capakey) | Regio | Oppervlakte | Gebouwen | Hoogte / verd. |
|---|---|---|---|---|
| 25743G0274/00E002 | Wallonië | 18,8 ha | 1 · 5.615 m² | - |
| 21307F0123/00P000 | Brussel | 3,9 ha | 1 · 4.201 m² | 18,7 m · 4 verd. |
Eén tijdlijn van alles wat er met dit bedrijf is gebeurd, publicaties, insolventie- en levensloopgebeurtenissen, administratieve wijzigingen en neergelegde jaarrekeningen.
02-01-2026 Statutenwijziging
Technische details
{
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"statute_change": {
"name_change": false,
"seat_change": false,
"object_change": false,
"effective_date": "2025-12-23",
"legal_form_change": false
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "1017.533.562",
"name_full": "UCB DEVELOPED BRANDS",
"legal_form": "SRL"
},
"signature_regime": null,
"special_mandates": [],
"governance_change": {
"admin_delegated_added": []
}
}02-10-2025 Wijziging in het bestuur
Technische details
{
"events": [],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "1017.533.562",
"name_full": "UCB DEVELOPED BRANDS",
"legal_form": "SRL"
}
}11-06-2025 Publicatie in het Belgisch Staatsblad, Diversen
Technische details
{
"stage": null,
"notary": {
"name": null,
"firm_city": null,
"firm_name": null,
"office_city": "Bruxelles",
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": "2025-06-11",
"filing_date": "2025-06-03",
"act_kind_objet": ""
},
"decision": {
"body": "enig_aandeelhouder_schriftelijk",
"act_date": "2025-05-26",
"unanimous": true
},
"conversion": null,
"detected_kind": "substantive_delegation",
"report_waiver": null,
"restructuring": {
"parties": [
{
"kbo": "1017.533.562",
"name": "UCB Developed Brands",
"role": "contributor",
"address": "All\u00E9e de la Recherche 60 - 1070 Bruxelles (Anderlecht)",
"is_foreign": false,
"legal_form": "Soci\u00E9t\u00E9 \u00E0 Responsabilit\u00E9 Limit\u00E9e",
"is_new_company": false,
"jurisdiction_country": null
}
],
"exchange_ratio": null,
"legal_articles": [
"2:8 \u00A74"
],
"is_cross_border": false,
"is_silent_merger": false,
"balance_basis_date": null,
"exchange_ratio_text": null,
"new_shares_issued_n": null,
"real_estate_included": false,
"patrimony_description": null,
"equity_transferred_eur": null,
"accounting_effective_date": null
},
"subject_company": {
"kbo": "1017.533.562",
"name_full": "UCB Developed Brands",
"legal_form": "Soci\u00E9t\u00E9 \u00E0 Responsabilit\u00E9 Limit\u00E9e"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Philip Van Nevel",
"org_rep_person_name": null
},
"summary_narrative": "Cette communication de d\u00E9p\u00F4t informe que toutes les actions de la soci\u00E9t\u00E9 UCB Developed Brands sont r\u00E9unies en une seule main, identifiant ainsi l\u0027actionnaire unique. Une procuration sp\u00E9ciale est octroy\u00E9e \u00E0 plusieurs personnes et \u00E0 l\u0027avocat de Freshfields Bruckhaus Deringer LLP pour accomplir les formalit\u00E9s de publication des r\u00E9solutions des administrateurs.",
"co_filed_documents": [
"R\u00E9solutions \u00E9crites des administrateurs de la soci\u00E9t\u00E9 du 26 mai 2025"
],
"detected_real_type": "substantive_delegation",
"referenced_correction": null,
"should_reroute_to_category": null
}12-05-2025 Statutenwijziging
Technische details
{
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"statute_change": {
"name_change": false,
"seat_change": false,
"object_change": false,
"effective_date": "2025-05-01",
"legal_form_change": false
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "1017.533.562",
"name_full": "UCB DEVELOPED BRANDS",
"legal_form": "SRL"
},
"signature_regime": null,
"special_mandates": [
{
"quote": "\u00E0 Matthieu Derynck et tout autre notaire belge et tout employ\u00E9 de l\u2019\u00E9tude des notaires \u00AB Van Halteren Notaires \u00BB, agissant s\u00E9par\u00E9ment, en vue d\u2019\u00E9tablir le texte coordonn\u00E9 des statuts",
"holder_kbo": null,
"holder_name": "Matthieu Derynck",
"scope_categories": [
"publication",
"filing"
],
"with_substitution": false
},
{
"quote": "\u00E0 Matthieu Derynck et tout autre notaire belge et tout employ\u00E9 de l\u2019\u00E9tude des notaires \u00AB Van Halteren Notaires \u00BB, agissant s\u00E9par\u00E9ment, en vue d\u2019\u00E9tablir le texte coordonn\u00E9 des statuts",
"holder_kbo": null,
"holder_name": "Van Halteren Notaires",
"scope_categories": [
"publication",
"filing"
],
"with_substitution": false
}
],
"governance_change": {
"admin_delegated_added": []
}
}18-03-2025 Publicatie in het Belgisch Staatsblad, Diversen
Technische details
{
"stage": "proposal",
"notary": {
"name": "Samuel Wynant",
"firm_city": null,
"firm_name": null,
"office_city": null,
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": "2025-03-18",
"filing_date": "2025-03-14",
"act_kind_objet": "DIVERS"
},
"decision": {
"body": null,
"act_date": "2025-03-14",
"unanimous": true
},
"conversion": null,
"detected_kind": "demerger_partial",
"report_waiver": null,
"restructuring": {
"parties": [
{
"kbo": "0543.573.053",
"name": "UCB Biopharma",
"role": "demerged",
"address": "All\u00E9e de la Recherche 60, 1070 Anderlecht",
"is_foreign": false,
"legal_form": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e",
"is_new_company": false,
"jurisdiction_country": "BE"
},
{
"kbo": "1017.533.562",
"name": "UCB Developed Brands",
"role": "recipient",
"address": "All\u00E9e de la Recherche 60, 1070 Anderlecht",
"is_foreign": false,
"legal_form": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e",
"is_new_company": false,
"jurisdiction_country": "BE"
}
],
"exchange_ratio": null,
"legal_articles": [
"12:8, 1\u00B0",
"12:4",
"12:59",
"12:67",
"12:69",
"12:62",
"12:13, 3\u00B0",
"12:60"
],
"is_cross_border": false,
"is_silent_merger": false,
"balance_basis_date": null,
"exchange_ratio_text": "une action ordinaire d\u2019UCB Developed Brands",
"new_shares_issued_n": 32383629,
"real_estate_included": false,
"patrimony_description": "Les actifs et passifs relatifs au Portfolio Mature, comprenant principalement les m\u00E9dicaments Cimzia\u00AE, Keppra\u00AE et Briviact\u00AE, seront scind\u00E9s et apport\u00E9s \u00E0 UCB Developed Brands.",
"equity_transferred_eur": null,
"accounting_effective_date": null
},
"subject_company": {
"kbo": "1017.533.562",
"name_full": "UCB Biopharma",
"legal_form": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e",
"_kbo_extracted_mismatch": "0543.573.053"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Samuel Wynant",
"org_rep_person_name": null
},
"summary_narrative": "Les conseils d\u2019administration d\u2019UCB Biopharma et UCB Developed Brands ont approuv\u00E9 un projet de scission partielle pour transf\u00E9rer les actifs et passifs du Portfolio Mature d\u2019UCB Biopharma \u00E0 UCB Developed Brands en \u00E9change de nouvelles actions ordinaires \u00E9mises par cette derni\u00E8re. L\u0027op\u00E9ration est pr\u00E9vue pour entrer en vigueur le 1er mai 2025.",
"co_filed_documents": [],
"detected_real_type": "demerger_proposal",
"referenced_correction": null,
"should_reroute_to_category": null
}19-12-2024 Oprichting van een SRL
Technische details
{
"kind": "oprichting",
"seat": "All\u00E9e de la Recherche 60, 1070 Anderlecht",
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"founders": [
{
"org": {
"kbo": "0403.096.168",
"name": "UCB PHARMA"
},
"kind": "rechtspersoon",
"person": null,
"share_class": "unique",
"partner_role": null,
"holder_org_kbo": "0403.096.168",
"holder_org_name": "UCB PHARMA",
"contribution_type": "cash",
"amount_paid_in_eur": 50000,
"holder_person_name": null,
"is_subscriber_only": true,
"n_shares_subscribed": 1,
"amount_subscribed_eur": 50000,
"is_anonymous_silent_partner": false
}
],
"capital_eur": 50000,
"subject_company": {
"kbo": "1017.533.562",
"name_full": "UCB Developed Brands",
"legal_form": "SRL"
},
"initial_directors": [],
"incorporation_date": "2024-12-13",
"post_incorporation_mandates": []
}Genereer een gestructureerde, feitelijke nota op basis van alle signalen in dit dossier: risico, financiële gezondheid, eigendomsstructuur, mandaten en sectorvergelijking.
| Officiële naamFR | UCB Developed Brands |